Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes.

Motonori SatoYoshifumi TamuraHideyoshi KagaNozomu YamasakiMai KiyaSatoshi KadowakiDaisuke SugimotoTakashi FunayamaYuki SomeyaSaori KakehiShuko NojiriHiroaki SatohRyuzo KawamoriHirotaka Watada

Published in: Biomedicines (2021)

MCRI did not change after a single dose or 8 weeks of tofogliflozin. Increased MCRI does not precede a decrease in body fat or improved glycemic control.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
gestational age
cardiovascular disease
blood pressure
drug induced